Improve the diagnosis and clinical management of patients and develop personalized medicine.

(1) To develop new biomarkers (substances used as indicators of a biological state) that make it possible to predict the prognosis of patients when they are admitted (better and worse, the latter being defined as admission to the ICU), which would allow a more rational use of healthcare resources.

(2) To evaluate the effect that immunomodulating compounds (with the ability to stimulate or depress the immune system by helping the body to fight infection) can have on each patient individually in order to design a personalized medicine that will improve the treatment of the disease.

Principal Investigator: David Bernardo (IBGM – UVA)